Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spruce Biosciences, Inc. - Common Stock (NQ:SPRB)

82.15 +3.08 (+3.90%)
Streaming Delayed Price Updated: 10:26 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Spruce Biosciences, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces $50.0 Million Private Placement Financing
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Reverse Stock Split
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder
From HMNC Holding GmbH
Via GlobeNewswire
News headline image
Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
Via AB Newswire
News headline image
Spruce Biosciences Recognized as a Bay Area Best Place to Work
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences to Participate in May Investor Conferences
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
From Spruce Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.